ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 318 for:    Recruiting, Not yet recruiting, Available Studies | "Brain Injuries, Traumatic"

Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate (HPTBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03502967
Recruitment Status : Not yet recruiting
First Posted : April 19, 2018
Last Update Posted : April 25, 2018
Sponsor:
Information provided by (Responsible Party):
Jae Mo Park, University of Texas Southwestern Medical Center

Brief Summary:
This project is to evaluate sensitivity and specificity of hyperpolarized 13C-pyruvate as imaging agents of altered cerebral glycolysis and mitochondrial dysfunction and assess pyruvate utilization in mitochondria in Traumatic Brain Injury (TBI) patients.

Condition or disease Intervention/treatment Phase
Traumatic Brain Injury Drug: Hyperpolarized [1-13C] Pyruvate Drug: Hyperpolarized [2-13C] Pyruvate Early Phase 1

Detailed Description:

Aim 1:

Investigators will quantify changes in [1-13C]lactate and H13CO3- labeling following a bolus injection of hyperpolarized [1-13C]pyruvate during the time window of secondary injury to assess upregulated glycolysis. Due to heterogeneous presence and severity of damage by TBI, defining the injured brain region can be difficult. Therefore, the metabolite ratio maps ([product]/[pyruvate]) of TBI patients (n = 5) will be compared with those of healthy-controls (n = 3).

Hyperpolarized [2-13C]pyruvate will be examined in a separate group of TBI cohorts (n = 5) and healthy controls (n = 3), and [5-13C]glutamate, [1-13C]acetyl-carnitine, [1-13C]acetoacetate, and [1-13C]citrate from [2-13C]pyruvate will be quantified for assessing the altered mitochondrial metabolism. Imaging procedure with [2-13C]pyruvate is the same as the imaging with hyperpolarized [1-13C]pyruvate.

For both [1-13C]pyruvate and [2-13C]pyruvate studies, each subject will be imaged twice with a 45min interval for confirming the reproducibility of the methods and/or averaging to enhance the signal-to-noise ratios of 13C-metabolite maps.

Aim 2:

After the feasibility study (aim1) is completed, an intra-subject comparison study of [1-13C]pyruvate and [2-13C]pyruvate will be performed. Similar to the aim1, patients with post-TBI neurological disorders having normal or near-normal CT results (n = 6 patients) as well as normal brains of age/gender-matching healthy volunteers (n = 3) will be recruited. Each patient will be imaged twice (one with [1-13C]pyruvate and one with [2-13C]pyruvate with a 45min interval). PDH activity and the TCA cycling will be assessed from measured H13CO3- from hyperpolarized [1-13C]pyruvate and [5-13C]glutamate from [2-13C]pyruvate, respectively. The comparison of [1-13C]pyruvate and [2-13C]pyruvate will identify the detailed information of how pyruvate (and converted acetyl-CoA) is utilized in the mitochondria, and assess the utility and necessity of imaging hyperpolarized [2-13C]pyruvate in TBI, providing critical data for future grant applications and larger clinical trials.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: TBI patients and healthy control subjects
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate
Estimated Study Start Date : May 1, 2018
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2020

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Hyperpolarized [1-13C] Pyruvate
Injection with hyperpolarized [1-13C] Pyruvate during MRI.
Drug: Hyperpolarized [1-13C] Pyruvate
Bolus injection of study drug
Other Name: HP Pyruvate Injection
Experimental: Hyperpolarized [2-13C] Pyruvate
Injection with hyperpolarized [2-13C] Pyruvate during MRI.
Drug: Hyperpolarized [2-13C] Pyruvate
Bolus injection of study drug
Other Name: HP Pyruvate Injection



Primary Outcome Measures :
  1. [1-13C]lactate-to-H13CO3- ratio from [1-13C]pyruvate or [2-13C]lactate-to-[5-13C]glutamate ratio from [2-13C]pyruvate [ Time Frame: One visit of three hours: 2 bolus injections during MRI with 45 minute rest period between the two ]
    Product ratio maps of lactate from pyruvate in the brain of TBI patients as compared to those of healthy controls.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

TBI Patients

  • Injury occurred within 10 days
  • Documented and verified TBI by Glascow coma scal 10-15 and/or Loss of Consciousness >10 minutes.
  • Head Computed Tomography at admission.

ALL Subjects:

  • 18 through 60 years of age.
  • Ability to understand the the willingness to sign a writteninformed consent.
  • All races and ethnicities will be included; subjects must be able to read and speak either the English or Spanish language.

Exclusion Criteria:

  • Non-traumatic structural brain abnormality identified on head CT.
  • Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions.
  • Penetrating TBI.
  • Significant anatomic distortion of the brain identified on CT images, such as large hematomas, herniation, intraventricular hemorrhage, extensive subarachnoid hemorrhage, hydrocephalus.
  • Significant polytrauma that would interfere with follow-up and outcome assessment.
  • Patients on psychiatric hold.
  • Major debilitating mental health disorders including, but not limited to schizophrenia and bipolar disorder that would limit compliance with study requirements.
  • Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements.
  • Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning.
  • Any contraindication per MRI Screening Form including
  • Implants contraindicated at 3T, pacemakers
  • Implantable Cardioverter Defibrillator (ICD)
  • Claustrophobia
  • Prisoners or patients in custody.
  • Medically unstable including
  • Heart failure
  • Severe left ventricular outflow tract (LVOT) obstruction
  • Unstable angina
  • Pregnancy
  • Lactating
  • Subjects who are receiving any other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03502967


Contacts
Contact: Jeannie D Baxter, RN 214-645-2726 jeannie.baxter@utsouthwestern.edu
Contact: Lucy H Christie, BSN, RN 214-645-2215 lucy.christie@utsouthwestern.edu

Sponsors and Collaborators
University of Texas Southwestern Medical Center

Responsible Party: Jae Mo Park, Principal Investigator, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT03502967     History of Changes
Other Study ID Numbers: STU 072017-009
First Posted: April 19, 2018    Key Record Dates
Last Update Posted: April 25, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jae Mo Park, University of Texas Southwestern Medical Center:
Traumatic Brain Injury
TBI

Additional relevant MeSH terms:
Wounds and Injuries
Brain Injuries
Brain Injuries, Traumatic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System